CTI, Humanigen Inc. dose first COVID-19 patient with FDA-approved lenzilumab proprietary antibody
Covington’s CTI partner, Humanigen Inc., has announced that the first COVID-19 patient has been dosed with its FDA-approved proprietary antibody…
Humanigen
Read More
Covington-based CTI partners with Humanigen for study of Lenzilumab for treatment of Coronavirus
Covington-based CTI Clinical Trial and Consulting Services has partnered with California-based Humanigen, Inc. on a study for the treatment of novel…